Alpha-synuclein Overview
Molecule Name
Synuclein alpha
Synonyms
NACP, PARK1, PARK4, PD1
Drug Development Progress
Drugs in Clinical Trials25
Approved Drugs0
Highest Development StagePhase 3 Clinical
Target Synonym
Truncated Alpha Synuclein，Α-Synuclein，PARK1，SNCA，Synuclein Alpha，Synuclein， Alpha (Non A4 Component Of Amyloid Precursor)，NACP，Parkinson Disease (Autosomal Dominant， Lewy Body) 4，Non-A4 Component Of Amyloid Precursor，Non A4 Component Of Amyloid Precursor，Non A-Beta Component Of AD Amyloid，Non-A Beta Component Of AD Amyloid，Synuclein Alpha-140，I+/--Synuclein，α-Synuclein，PARK4，alpha-Synuclein
Background
Alpha-synuclein is a neuronal protein that plays several roles in synaptic activity such as regulation of synaptic vesicle trafficking and subsequent neurotransmitter release. It acts also as a molecular chaperone in its multimeric membrane-bound state, assisting in the folding of synaptic fusion components called SNAREs (Soluble NSF Attachment Protein REceptors) at presynaptic plasma membrane in conjunction with cysteine string protein-alpha/DNAJC5. Abnormalities in alpha-synuclein are implicated in the pathogenesis of Parkinson's disease (PD). Alpha-synuclein is present in Lewy-bodies, the neuropathological hallmark of PD, and the protein and its aggregation have been widely linked to neurotoxic pathways that ultimately lead to neurodegeneration.
Alpha-synuclein Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Buntanetap | ANVS-405; ANVS-401 | Phase 3 Clinical | Raptor Pharmaceutical | Alzheimer Disease; Chronic Traumatic Encephalopathy; Cognitive Dysfunction; Down Syndrome; Frontotemporal Dementia; Parkinson Disease | Details |
| Amlenetug | Lu AF-82422; Lu AF82422; Lu-AF82422 | Phase 3 Clinical | Genmab A/S, H. Lundbeck A/S | Multiple System Atrophy; Parkinson Disease | Details |
| Prasinezumab | PRX-002; RG-7935; NEOD-002; RO-7046015 | Phase 3 Clinical | Prothena | Parkinson Disease | Details |
| Kenterin | ENT-01; kenterin; Enterin-01 | Phase 2 Clinical | Enterin Inc | Constipation; Dementia; Parkinson Disease | Details |
| PBT-434 | PBT-434; ATH-434 | Phase 2 Clinical | Prana Biotechnology Ltd | Multiple System Atrophy | Details |
| MT101-5 | MT101-5 | Phase 2 Clinical | Mthera Pharma Co Ltd | Parkinson Disease | Details |
| AMDX-2011P | AMDX2011P; AMDX-2011P | Phase 2 Clinical | Amydis Inc | Alzheimer Disease; Amyotrophic Lateral Sclerosis; Cerebral Amyloid Angiopathy; Glaucoma, Open-Angle; Parkinson Disease | Details |
| ACI-7104 | ACI-7104.056; ACI-7104 | Phase 2 Clinical | Ac Immune Sa | Parkinson Disease | Details |
| Minzasolmin | UCB-1332; NPT200-11; DLX-313; DLX313; UCB-0599 | Phase 2 Clinical | Neuropore Therapies Inc | Parkinson Disease | Details |
| Exidavnemab | PD-0805; BAN-0805; BBV-0805; ABBV-0805; PR-1808164 | Phase 2 Clinical | Bioarctic Ab | Multiple System Atrophy; Parkinson Disease | Details |
| Emrusolmin | TEV-56286; TEV-'286; Anle-138b; TEV-286 | Phase 2 Clinical | Ludwig-Maximilians-University, Max Planck Institute for Biophysical Chemistry | Multiple System Atrophy; Parkinson Disease | Details |
| ION-464 | BIIB-101; IONIS-BIIB6 Rx; ION-464 | Phase 1 Clinical | Ionis Pharmaceuticals Inc | Multiple System Atrophy | Details |
| UB-312 | UB-312 | Phase 1 Clinical | United Neuroscience Ltd | Multiple System Atrophy; Parkinson Disease; Parkinsonian Disorders | Details |
| SAR-446159 | SAR-446159; ABL-301 | Phase 1 Clinical | Abl Bio Inc | Parkinson Disease | Details |
| SST-001 | SST001; SST-001; 18F-FD4 | Phase 1 Clinical | SynuSight Biotech (Shanghai) Co Ltd | Diagnostic agents; Lewy Body Disease; Multiple System Atrophy; Parkinson Disease; Synucleinopathies | Details |
| 18F-CP6A | 18F-CP6A | Phase 1 Clinical | Shenzhen Braegen Pharmaceutical Co Ltd | Synucleinopathies | Details |
| AB-16 | AB-16 | Phase 1 Clinical | Autotac Bio Inc | Parkinson Disease | Details |
| ACI-12589 | ACI-12589; a-syn-PET tracer (AC Immune); [18F]MNI-1216; [18F]ACI-12589 | Phase 1 Clinical | Ac Immune Sa, Biogen Inc, Invicro Llc | Lewy Body Disease; Multiple System Atrophy; Parkinson Disease; Synucleinopathies | Details |
| PK-081 | PK081; PK-081 | Phase 1 Clinical | PharmaKure Ltd | Parkinson Disease | Details |
| [11C]SY-08 | [11C]SY-08; [11C]SY08 | Phase 1 Clinical | Massachusetts General Hospital | Lewy Body Disease; Multiple System Atrophy; Parkinson Disease | Details |
| SNP201 | SNP201; SNP-201 | Phase 1 Clinical | SciNeuro Pharmaceuticals | Parkinson Disease | Details |
| [18F]UCB-2897 | UCB-2897; [18F]UCB-2897 | Phase 1 Clinical | Invicro Llc | Multiple System Atrophy; Parkinson Disease | Details |
| ACI-3847 | ACI-3847; 18F-ACI-3847 | Phase 1 Clinical | Ac Immune Sa, Biogen Inc | Neurodegenerative Diseases; Parkinson Disease | Details |
| UCB-7853 | UCB-7853 | Phase 1 Clinical | Ucb Biopharma Srl | Parkinson Disease | Details |
| Syneuro (Indus Biotech) | Clinical | Indus Biotech Pvt Ltd | Parkinson Disease | Details |